Global Chronic Kidney Disease (CKD) Anemia Market Size, Share, Growth & Trends Report Segmented by Treatment (Iron Supplements, ESAs, Vitamin B12), Formulation (Tablets, Injectable), Product (OTC, Rx), End User (Hospitals, Online, Retail) Industry Analysis & Regional Forecast to 2031

Chronic Kidney Disease (CKD) Anemia is a commonly seen adverse outcome of CKD defined by low amounts of hemoglobin in the bloodstream because of altered kidney function. Under normal circumstances, healthy kidneys create erythropoietin, which is a hormone that promotes the production of red blood cells in the bone marrow. Under conditions of CKD, the combination of low production of erythropoietin, low levels of iron in the body, inflammation and decreased lifespan of red blood cells lead to the development of anemia associated with CKD. Symptoms of CKD anemia include fatigue, malaise, dyspnea, and generally lower quality of life than those that do not suffer with CKD anemia. CKD anemia has also been associated with increased risk of cardiovascular events, more rapid progression of CKD and increased morbidity and mortality if the anemia is left untreated.

Rising prevalence of chronic kidney disease and associated anemia to propel market demand

One of the main contributors to the growth of the CKD anemia market is the increasing number of people diagnosed with chronic kidney disease and the associated complications of anemia. The rise in CKD and concurrent low blood counts or anemia is a key factor driving the growth of the CKD anemia market. Approximately 700 million people are estimated to have CKD worldwide (Source: NCBI). The global incidence of CKD is rising due to the growing burden of diabetes, high blood pressure, obesity, heart diseases, and aging population. Diabetes and high blood pressure alone account for a very large part of CKD cases, in both developed and developing countries. The total number of patients who develop moderate to advanced CKD will continue to increase, as these two underlying causes continue to grow.

As kidney function declines, anemia becomes more prevalent. The kidneys, when damaged, make less erythropoietin, a hormone that stimulates the production of red blood cells. In addition to erythropoietin deficiency, CKD patients often also suffer from iron deficiency, chronic inflammation, and shortened life spans of their red blood cells which all contribute to developing anemia. Anemia is very common in stages 3 to 5 CKD, especially amongst those patients on dialysis. With the growth in CKD patient population, an equal growth in addressable patient population requiring anemia management will be seen, thus increasing the demand for treatment options for these patients.

Unmanaged anemia due to CKD leads to further expansion of this category of drugs. People with CKD who also suffer from anemia experience fatigue, a decrease in functioning during physical activity, impaired cognitive function, and a compromise in their overall health. Most importantly, CKD-related anemia contributes to increased rates of heart disease, hospitalization, and death. Due of this, physicians have been focusing more on identifying CKD-related anemia as quickly as possible so they can begin treating these patients to improve health and to reduce long-term healthcare costs associated with patients getting CKD-related anemia. There is thus, a consistent use of erythropoietin stimulating agents, iron therapies, and the more recently available hypoxia-inducible factor prolyl hydroxylase inhibitors.

In addition, the implementation of screening programs and increased awareness of diagnosis are resulting in earlier identification of anemia related to CKD, including use of patients not yet on dialysis, thereby increasing the total number of people who meet the criteria for treatment. Emerging markets are also witnessing rising CKD detection rates as healthcare infrastructure improves, further enlarging global demand. Thus, the continued increase in the prevalence of CKD creates a base of expanding patients with CKD who will continue to seek treatment for CKD-related anemia leading to consistent long-term expansion of the CKD anemia-related therapeutic market.

To learn more about this report, download the PDF brochure

Therapeutic innovation and new treatment options is driving the market growth

Therapeutic innovation and the introduction of new treatment options are significantly driving growth in the CKD anemia market by improving clinical outcomes, expanding the eligible patient population, and increasing treatment adoption. Traditionally, CKD anemia management relied heavily on erythropoiesis-stimulating agents (ESAs) and iron supplementation. While effective, ESAs are associated with safety concerns such as cardiovascular risks, hypertension, and thromboembolic events, particularly at higher hemoglobin targets. These limitations created a strong need for safer, more convenient, and more physiologically aligned treatment alternatives.

The development of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors represents a major therapeutic advancement. Unlike ESAs, which rely on exogenous stimulation of erythropoietin, HIF-PH inhibitors stimulate endogenous erythropoietin production and enhance iron metabolism through a mechanism that mimics the body’s natural response to hypoxia. This innovation not only improves hemoglobin levels but also addresses functional iron deficiency, a common challenge in CKD patients. Additionally, many HIF-PH inhibitors are available in oral formulations, offering greater convenience compared to injectable ESAs. Oral administration improves patient adherence, particularly among non-dialysis CKD patients, thereby expanding treatment penetration outside dialysis centers. Market growth for long-acting ESAs and improved intravenous iron formulations has been influenced by the development of these newer products as they allow less frequently administered doses, enable increased patient comfort, and increase efficiencies within dialysis clinics due to streamlining their administration. These types of products decrease the frequency of dosing, aid in lowering healthcare resource utilization, and increase adherence, therefore allowing for wider acceptance of such treatment by all healthcare providers.

Continued clinical trials for the management of anemia continue to identify new treatment strategies including, among other things, combination therapies and individualized dosing regimens for patients based upon various factors including iron level, elevated inflammation markers, and stage of CKD. The use of precision medicine enables better efficacy while also minimizing side effects, resulting in greater provider confidence with respect to treatment. The approval of novel agents by the regulatory bodies in multiple countries continues to accelerate commercialization of products and results in increased competition among companies. Numerous pharmaceutical manufacturers are investing heavily in research and development, entering strategic partnerships, and implementing lifecycle management strategies to enhance the anemia portfolios of their product line.

Innovation in therapeutics is moving CKD anemia away from just the management of symptoms to creating a more targeted and patient friendly treatment plan, allowing for the expansion of the market and the potential for continued long-term growth.

Growth strategies adopted by players to establish their foothold in the market

Players operating in this market are adopting various growth strategies such as new product launches and approvals, and strategic partnerships, agreements, and collaborations to garner market share. For instance,

• In December 2025, Insilico Medicine entered an exclusive licensing agreement with TaiGen Biotechnology, granting TaiGen rights in Greater China to develop and commercialize ISM4808, an AI-designed oral PHD inhibitor for anemia of CKD. The deal includes upfront, milestone, and royalty payments, and aims to accelerate clinical development of ISM4808, which received IND clearance in China in 2023

• In September 2025, Sandoz launched a generic iron sucrose injection in the US following FDA approval to treat iron deficiency anemia, including in patients with CKD. The launch expands affordable access to intravenous iron therapy, strengthens US supply, and builds Sandoz’s injectable iron portfolio
• In March 2024, the US FDA approved Vafseo (vadadustat), an oral HIF-PHI developed by Akebia, for the treatment of anemia due to CKD in adults on dialysis for at least three months. The approval was based on Phase 3 INNO2VATE data, and CSL Vifor received exclusive rights to commercialize Vafseo in Fresenius Kidney Care centers and other dialysis organizations covering about 60% of US dialysis patients
• In February 2023, GSK received US FDA approval for Jesduvroq (daprodustat), the first and only oral HIF-PHI in the US for treating anemia of CKD in adults on dialysis. The approval, based on Phase III ASCEND-D trial results, introduces a major innovation in CKD anemia and provides a convenient once-daily oral alternative to ESAs

To learn more about this report, download the PDF brochure

Treatment Segment Outlook

Erythropoietins/Erythrocyte Stimulating Agents (ESAs) account for the largest segment of the chronic kidney disease anemia market. ESAs are considered part of the routine treatment protocol to promote red blood cell formation, especially among patients on dialysis; therefore, they are well-established in terms of clinical efficacy, reimbursement mechanisms, and strong prescribing patterns throughout the developed world. The fastest growing segment is iron supplements, which are rapidly gaining momentum as clinicians are increasingly aware of the need to manage iron deficiency, while additionally having access to improved intravenous iron formulations, and are also being used in conjunction with ESAs to improve response rate to ESA therapy. The significant increase in emphasis on optimizing hemoglobin levels while reducing the number of ESAs used will continue to drive demand for iron therapies.

Regional Outlook: North America expected to hold a major share in the CKD anemia market

North America represents the largest regional segment in the chronic kidney disease anemia market, supported by a high incidence of CKD, a well-established process for diagnosing CKD patients, the presence of established dialysis network, and favorable reimbursement programs for CKD patients (both in the US and Canada). Europe's CKD anemia market ranks second in size due to a set of clinical treatment guidelines and broad access to erythropoiesis-stimulating agents (ESAs) and iron therapies for CKD patients. Asia Pacific is the third largest region in terms of revenue and the fastest growing regional market for CKD anemia therapies. Rapidly growing CKD patient populations, expanding healthcare systems, improved access to dialysis, increased healthcare spending in countries like China and India, growing public health awareness, and government programs all contribute to the rapid growth of the CKD market within Asia Pacific countries.

Competitive Landscape Analysis

The global CKD anemia market is marked by the presence of established and emerging market players such as Amgen Inc (US); F. Hoffmann-La Roche Ltd (Switzerland); Pfizer Inc (US); GlaxoSmithKline plc (UK); Johnson & Johnson (US); CSL Vifor (Switzerland); AstraZeneca plc (UK); Akebia Therapeutics, Inc (US); Bayer AG (Germany); and Sandoz Inc. (Switzerland); among others. Some of the key strategies adopted by market players include new product launches and approvals, and strategic partnerships, agreements, and collaborations.

Get a sample report for competitive landscape analysis

Report Scope

Global CKD Anemia Market Segmentation

This report by Medi-Tech Insights provides the size of the global CKD anemia market at the regional- and country-level from 2024 to 2031. The report further segments the market based on treatment, formulation type, product type, dosage form, route of administration, age group, and sales channel.

Market Size & Forecast (2024-2031), By Treatment, USD Billion

• Iron Supplements
• Erythropoietin/Erythrocyte‑Stimulating Agents (ESAs)
• Vitamin B12 Supplements
• Folic Acid Supplements
• Other Treatments

Market Size & Forecast (2024-2031), By Formulation Type, USD Billion

• Tablets
• Injectable
• Other Formulations

Market Size & Forecast (2024-2031), By Product Type, USD Billion

• Over‑the‑Counter (OTC)
• Prescription (Rx)

Market Size & Forecast (2024-2031), By Dosage Form, USD Billion

• Solid
• Liquid

Market Size & Forecast (2024-2031), Route of Administration, USD Billion

• Oral
• Parenteral

Market Size & Forecast (2024-2031), Age Group, USD Billion

• Pediatrics
• Adults
• Geriatrics

Market Size & Forecast (2024-2031), Sales Channel, USD Billion

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports:

Continuous Renal Replacement Therapy (CRRT) Market By Product (CRRT Systems, Disposables, Hemofilters), By Modality (Continuous Venovenous Hemofiltration (CVVH), Slow Continuous Ultrafiltration (SCUF)), By End User (Hospital, Ambulatory) To Forecast 2031

Hematology Market Size, Share, Analysis by Product (Instrument (PoC, Semi-automated), Reagent, Consumable, Service), Price (High, Mid, Low), Application (Anemia, Blood Cancer), End User (Hospital, CTL, Govt Lab, Blood Bank) and Regional Forecast to 2031

Global Dialysis Market Size & Trends Report Segmented by Product & Service (Device, Consumables, Services), Dialysis Type (Hemodialysis, Peritoneal Dialysis), End-user (Hospitals, Home Care, Others) Industry Growth Analysis & Regional Forecasts to 2030